Pancreatic cancer is one of the cancers with the poorest prognosis, with a 5-year survival rate of just 13% in the United States, for all stages combined1. Diagnosis most often occurs at an advanced stage of the disease, when the tumor can no longer be operated on as a result of the late clinical expression of the disease.
According to the 2024 global estimates, pancreatic cancer ranks 11th in incidence and sixth among causes of cancer death worldwide.2 Adjusted for population, the number of new cases is increasing considerably, approaching one million new cases, particularly the case in Asia as well as in countries across Europe and North America.
Established or associated risk factors include smoking, excess body weight, diabetes, chronic pancreatitis, alcohol consumption, and certain inherited predispositions, including alterations involving BRCA1, BRCA2, and PALB2.3
531,318
new cases worldwide in 20242.
Over 490,000
people died from pancreatic cancer worldwide in 20244.
The pancreas, an essential digestive organ
A diagnosis made too late
The poor prognosis of pancreatic cancer is largely explained by its late diagnosis. The patient starts getting the first signs when the cancer is already at an advanced stage. Approximately 15–20% of pancreatic cancers are resectable at diagnosis. In the United States, the five-year relative survival rate is 44% for localized disease, compared with 13% for all stages combined.5
Among others, symptoms include a loss of appetite, weight loss, and stomach pain, which can extend to the sides and the back. If the tumor develops in the head of the pancreas, it causes compression of the common bile duct, which carries bile from the liver to the intestine. Bile then flows back into circulation, resulting in a yellowing of the eyes and the skin (jaundice), dark-colored urine, discolored stool, and sometimes itching of the skin.
Contrast-enhanced, pancreatic-protocol CT is the primary imaging examination. MRI and endoscopic ultrasound may complement the assessment when indicated. Regional lymph-node involvement and distant metastases, particularly in the liver, peritoneum, or lungs, are evaluated. Histological confirmation is not always required before upfront surgery, but is required before neoadjuvant treatment and for locally advanced or metastatic disease.6
Surgery, the only potential cure
The Whipple procedure removes the head of the pancreas, the duodenum, the gallbladder, and part of the bile duct; part of the stomach may also be removed, depending on the surgical technique.7
Chemotherapy, a therapeutic alternative
Chemotherapy plays a central role and is used in most patients who are able to receive anticancer treatment.8 The medicines employed stop cells from proliferating. They target rapidly dividing cells, whether cancerous or not – which explains the side effects of such treatments.
After surgery, chemotherapy is described as “adjuvant”: it seeks to eliminate residual cancer cells, and thus prevent relapse. In some cases, it can be performed before the operation, in order to reduce the tumor to an operable size. In this case, it is referred to as “neo-adjuvant”. When surgery has not been performed, chemotherapy helps control the tumor and alleviate symptoms. When the disease is at an advanced stage, it is most often based on the combination of several drugs to combine their actions.
Radiotherapy can also be used, in combination with chemotherapy, when the tumor is locally advanced but not operable. It may even be used to treat bone metastases, which are often painful.

About Servier
In oncology, Servier is building an innovation model designed around precision therapies for clearly defined patient populations with high unmet medical needs. Servier’s strategy is to concentrate its oncology efforts where the Group can build impact over time. Priority areas anchor this strategy: digestive cancers (colorectal cancer, gastric cancer, pancreatic cancer, cholangiocarcinoma), brain tumors (glioma and low-grade glioma), hematologic cancers (acute myeloid leukemia, acute lymphoblastic leukemia), and rare cancers.
REMEMBER
[1] American Cancer Society, Survival Rates for Pancreatic Cancer, Surveillance, Epidemiology, and End Results data for people diagnosed in 2015–2021, updated January 13, 2026
[2] International Agency for Research on Cancer, World Health Organization, Global Cancer Observatory: Cancer Today — GLOBOCAN 2024, Pancreas Fact Sheet, version 1.0, 2026.
[3] National Cancer Institute, Pancreatic Cancer Treatment, Health Professional Version, updated February 12, 2025; International Agency for Research on Cancer, Alcohol Intake and Pancreatic Cancer Risk: an Analysis from 30 Prospective Studies across Asia, Australia, Europe, and North America, press release dated May 23, 2025.
[4] International Agency for Research on Cancer, World Health Organization, Pancreatic Cancer, GLOBOCAN 2024 data, 2026.
[5] National Cancer Institute, Pancreatic Cancer Treatment, Health Professional Version, updated February 12, 2025; American Cancer Society, Survival Rates for Pancreatic Cancer, Surveillance, Epidemiology, and End Results data for 2015–2021, updated January 13, 2026.
[6] European Society for Medical Oncology, Pancreatic Cancer: Clinical Practice Guideline for Diagnosis, Treatment and Follow-up, 2023; National Comprehensive Cancer Network, Pancreatic Adenocarcinoma, Clinical Practice Guidelines in Oncology, version 4.2026.
[7] National Cancer Institute, Pancreatic Cancer Treatment, “Surgery” section, accessed in 2026.
[8] National Cancer Institute, Pancreatic Cancer Treatment, “Chemotherapy” section, accessed in 2026